These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
62. How pharmacogenomics will impact the federal regulation of clinical trials and the new drug approval process. Binzak BA Food Drug Law J; 2003; 58(1):103-27. PubMed ID: 12739592 [No Abstract] [Full Text] [Related]
63. Cardiac repolarization and the safety of new drugs defined by electrocardiography. Morganroth J Clin Pharmacol Ther; 2007 Jan; 81(1):108-13. PubMed ID: 17186008 [TBL] [Abstract][Full Text] [Related]
64. Is it time to rethink the expanded-access programs for HIV infection? Amorosa V; Tebas P J Infect Dis; 2007 Oct; 196(7):974-7. PubMed ID: 17763316 [TBL] [Abstract][Full Text] [Related]
65. Alternative strategies in drug development: clinical pharmacological aspects. Kuhlmann J Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949 [TBL] [Abstract][Full Text] [Related]
66. New drugs and product approvals from 2000. Taylor SE; Gage TW Tex Dent J; 2001 Nov; 118(11):1070-81. PubMed ID: 11806330 [No Abstract] [Full Text] [Related]
67. Current good manufacturing practice and investigational new drugs intended for use in clinical trials. Final rule. Food and Drug Administration, HHS Fed Regist; 2008 Jul; 73(136):40453-63. PubMed ID: 18850678 [TBL] [Abstract][Full Text] [Related]
68. Delayed-release prednisone (Rayos). Med Lett Drugs Ther; 2012 Nov; 54(1404):94. PubMed ID: 23183387 [No Abstract] [Full Text] [Related]
69. Cyclodextrins--enabling excipients: their present and future use in pharmaceuticals. Thompson DO Crit Rev Ther Drug Carrier Syst; 1997; 14(1):1-104. PubMed ID: 9043816 [TBL] [Abstract][Full Text] [Related]
70. Trends in antimicrobial drug development: implications for the future. Spellberg B; Powers JH; Brass EP; Miller LG; Edwards JE Clin Infect Dis; 2004 May; 38(9):1279-86. PubMed ID: 15127341 [TBL] [Abstract][Full Text] [Related]
71. Lost interest for existing compounds: New boosts. Friedhoff LT; Dailey J Eur Neuropsychopharmacol; 2015 Jul; 25(7):1035-8. PubMed ID: 25935092 [TBL] [Abstract][Full Text] [Related]
73. Translational research: The American way. Maxmen A Nature; 2011 Oct; 478(7368):S16-8. PubMed ID: 21993821 [No Abstract] [Full Text] [Related]
74. Products approved in the United States for marketing during 2000. Pieniaszek HJ J Clin Pharmacol; 2001 May; 41(5):479-81. PubMed ID: 11361043 [No Abstract] [Full Text] [Related]
75. Experimental drugs: where do you stand legally? Marchette L RN; 1984 Mar; 47(3):23-4. PubMed ID: 6366999 [No Abstract] [Full Text] [Related]
76. 2008 FDA drug approvals. Hughes B Nat Rev Drug Discov; 2009 Feb; 8(2):93-6. PubMed ID: 19180096 [No Abstract] [Full Text] [Related]
77. Intravenous acetaminophen (Ofirmev). Med Lett Drugs Ther; 2011 Apr; 53(1361):26-8. PubMed ID: 21464803 [No Abstract] [Full Text] [Related]
79. Trends in approval of new antimicrobial agents in India compared with the USA. Kataria BC; Mehta DS; Mehta SJ Int J Antimicrob Agents; 2012 Jul; 40(1):85-6. PubMed ID: 22591840 [No Abstract] [Full Text] [Related]